Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome

Abstract

This analysis of the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial examined the effectiveness and safety of ezetimibe 10 mg added to ongoing statin therapy in patients with diabetes, metabolic syndrome without diabetes, or neither disorder who had low-density lipoprotein cholesterol (LDL-C) levels exceeding National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) goals. After six weeks of treatment, ezetimibe added to statin reduced LDL-C in patients with diabetes by 28%, metabolic syndrome by 24%, or neither by 26%, compared with a 3% reduction for placebo for each group. In each group, more patients receiving ezetimibe plus statin reached LDL-C goal (67–74%) compared with those receiving placebo plus statin (19–22%). Other parameters demonstrating greater improvement with ezetimibe included triglycerides, apolipoprotein (Apo)B/Apo A-I ratio, high-density lipoprotein cholesterol (HDL-C), and C-reactive protein. Ezetimibe plus statin was well tolerated in each group. Ezetimibe added to ongoing statin therapy offers a new treatment option that is consistently effective in improvement of lipid profiles and attainment of LDL-C goals in patients with or without diabetes or metabolic syndrome.

Keywords

diabetes metabolic syndrome lipoproteins efficacy ezetimibe low-density lipoprotein cholesterol

References

1. Lee ET , Keen H , Bennett PH , Fuller JH , Lu M Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: general description and morbidity. Diabetologia 2001;44(suppl 2):S3–S13.

2. Wingard DL , Barrett-Connor E . Heart Disease and Diabetes. Diabetes in America. National Diabetes Data Group, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468, 1995:429–48.

3. Geiss LS , Herman WH , Smith PJ Mortality in Non-Insulin-Dependent Diabetes. Diabetes in America. National Diabetes Data Group, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468, 1995:233–57.

4. Morrish NJ , Wang SL , Stevens LK , Fuller JH , Keen H Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(suppl 2):S14–S21.

5. Syvanne M , Taskinen MR Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;50(suppl 1):SI20–SI23.

6. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733–49.

7. Turner RC , Millns H , Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823–8.

8. Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999;25(suppl 3):32–40.

9. Cannon CP , Braunwald E , McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504.

10.

10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.

11.

11. Sacks FM , Pfeffer MA , Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–09.

12.

12. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

13.

13. National Cholesterol Education Program (NCEP) . Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.

14.

14. Grundy SM , Cleeman JI , Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.

15.

15. Rosenson RS. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol 2005;30:241–79.

16.

16. Vijan S , Hayward RA Pharmacologic l ipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650–8.

17.

17. Foley KA , Simpson RJ, Jr. , Crouse JR, III , Weiss TW , Markson LE , Alexander CM . Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92(1):79–81.

18.

18. Marcelino JJ , Feingold KR Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605–10.

19.

19. Pearson TA , Laurora I , Chu H , Kafonek S The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67.

20.

20. Schectman G , Hiatt J Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197–204.

21.

21. Steiner G. The need for a different cholesterol lowering drug. Can J Clin Pharmacol 2003;10(suppl A):4A–6A.

22.

22. Sudhop T , Lutjohann D , Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943–8.

23.

23. Van Heek M , France CF , Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157–63.

24.

24. Van Heek M , Farley C , Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748–54.

25.

25. Deedwania PC , Hunninghake DB , Bays H Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol 2004;93(11A):18C–26C.

26.

26. Pearson TA , Denke MA , McBride PE , Battisti WP , Brady WE , Palmisano J A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercho-lesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587–95.

27.

27. Friedewald WT , Levy RI , Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.

28.

28. Buchwald H , Varco RL , Matts JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946–55.

29.

29. Gotto AM, Jr. , Whitney E , Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477–84.

30.

30. Sever PS , Dahlof B , Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.

31.

31. Shepherd J , Blauw GJ , Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30.

32.

32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesteral levels. N Engl J Med 1998;339:1349–57.

33.

33. Koren MJ , Hunninghake DB Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772–9.

34.

34. Haffner SM. Statin therapy for the treatment of diabetic dyslipidemia. Diabetes Metab Res Rev 2003;19:280–7.

35.

35. Colhoun HM , Betteridge DJ , Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96.

36.

36. World Helath Organization. Definition DaCoDMaiC, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: Department of Non-communicable Disease Surveillance 1. 2006.

37.

37. Einhorn D , Reaven GM , Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237–52.

38.

38. Zimmet PZ , Alberti KG , Shaw JE Mainstreaming the metabolic syndrome: a definitive definition. This new definition should assist both researchers and clinicians. Med J Aust 2005;183:175–6.

39.

39. Magliano DJ , Shaw JE , Zimmet PZ How to best define the metabolic syndrome. Ann Med 2006;38(1):34–41.

40.

40. George PB , Tobin KJ , Corpus RA , Devlin WH , O'Neill WW.

Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?

Am Heart J 2001;142:857–63.

41.

41. Saaddine JB , Engelgau MM , Beckles GL , Gregg EW , Thompson TJ , Narayan KM A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565–74.

42.

42. Saydah SH , Fradkin J , Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335–42.

43.

43. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999;84(1A):11J–14J.

44.

44. Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest 1999;29(suppl 2):12–16.

45.

45. Feingold KR , Grunfeld C , Pang M , Doerrler W , Krauss RM LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496–502.

46.

46. Laakso M. Lipids in type 2 diabetes. Semin Vasc Med 2002;2(1):59–66.

47.

47. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82(12A):67U–73U.

48.

48. Verges B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr Med Res Opin 2005;21(suppl 1):S29–S40.

49.

49. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68–S71.

50.

50. Smith SC, Jr. , Allen J , Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363–72.

51.

51. Dujovne CA , Ettinger MP , McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092–7.

52.

52. Gagne C , Gaudet D , Bruckert E Efficacy and safety of ezetimibe coad-ministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469–75.

53.

53. Gagne C , Bays HE , Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–91.

54.

54. Kerzner B , Corbelli J , Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418–24.

55.

55. Staels B , Fruchart JC Therapeutic roles of peroxisome proliferator-acti-vated receptor agonists. Diabetes 2005;54:2460–70.

56.

56. Bahl VK , Vaswani M , Thatai D , Wasir HS Plasma levels of apolipopro-teins A-1 and B in Indian patients with angiographically defined coronary artery disease. Int J Cardiol 1994;46:143–9.

57.

57. Kim HK , Chang SA , Choi EK et al. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. Int J Cardiol 2005;101:435–40.

58.

58. Meisinger C , Loewel H , Mraz W , Koenig W Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005;26:271–8.

59.

59. Reinhart RA , Gani K , Arndt MR , Broste SK Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990;150:1629–33.

60.

60. Sniderman AD , Furberg CD , Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777–80.

61.

61. Walldius G , Jungner I Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188–205.

62.

62. Walldius G , Jungner I , Holme I , Aastveit A , Kolar W , Steiner E High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001;358:2026–33.

63.

63. Yusuf S , Hawken S , Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.

64.

64. Goldberg AC , Sapre A , Liu J , Capece R , Mitchel YB Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620–9.

65.

65. Gaudiani LM , Lewin A , Meneghini L et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005;7(1):88–97.

66.

66. Goldberg RB, Teal GJM. Ezetimibe/simvastatin (E/S) vs atorvastatin in hypercholesterolemic (HC) patients with type 2 diabetes (T2DM). Poster presented at: Scientific Sessions of the American Diabetes Association;June 10-12, 2006; Washington, DC.

67.

67. Simons L , Tonkon M , Masana L et al. Effects of ezetimibe added to ongoing statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20:1437–45.